Literature DB >> 21863467

[Cardiovascular comorbidity and its risk factors in rheumatoid arthritis].

S Kleinert1, K Krueger.   

Abstract

Rheumatoid arthritis (RA) is still associated with an increased mortality mainly due to an increase in cardiovascular risk. This increase is not solely explained by traditional cardiovascular risk factors but also by disease characteristics, e.g. inflammation, positive rheumatoid factor and anti-citrullinated peptide antibodies (ACPA). Control of disease activity with disease-modifying drugs (DMARDs) was shown to reduce cardiovascular risk in RA patients. Use of non-steroidal antirheumatic drugs (NSAIDs) and glucocorticoids might be associated with an increased risk. The EULAR recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis have been established. These recommendations are based on national guidelines regarding control of traditional cardiovascular risk factors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21863467     DOI: 10.1007/s00393-011-0755-0

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  42 in total

1.  EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis.

Authors:  M J L Peters; D P M Symmons; D McCarey; B A C Dijkmans; P Nicola; T K Kvien; I B McInnes; H Haentzschel; M A Gonzalez-Gay; S Provan; A Semb; P Sidiropoulos; G Kitas; Y M Smulders; M Soubrier; Z Szekanecz; N Sattar; M T Nurmohamed
Journal:  Ann Rheum Dis       Date:  2009-09-22       Impact factor: 19.103

2.  Antirheumatic drug use and the risk of acute myocardial infarction.

Authors:  Samy Suissa; Sasha Bernatsky; Marie Hudson
Journal:  Arthritis Rheum       Date:  2006-08-15

3.  [The role of lipid metabolism in the prevention of coronary heart disease].

Authors:  P Mathes; J Thiery
Journal:  Z Kardiol       Date:  2005

4.  Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis.

Authors:  Jeffrey D Greenberg; Joel M Kremer; Jeffrey R Curtis; Marc C Hochberg; George Reed; Peter Tsao; Michael E Farkouh; Adeel Nasir; Soko Setoguchi; Daniel H Solomon
Journal:  Ann Rheum Dis       Date:  2010-11-24       Impact factor: 19.103

5.  Lipids, myocardial infarction and ischaemic stroke in patients with rheumatoid arthritis in the Apolipoprotein-related Mortality RISk (AMORIS) Study.

Authors:  A G Semb; T K Kvien; A H Aastveit; I Jungner; T R Pedersen; G Walldius; I Holme
Journal:  Ann Rheum Dis       Date:  2010-06-15       Impact factor: 19.103

Review 6.  The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review.

Authors:  Sarah L Westlake; Alexandra N Colebatch; Janis Baird; Patrick Kiely; Mark Quinn; Ernest Choy; Andrew J K Ostor; Christopher J Edwards
Journal:  Rheumatology (Oxford)       Date:  2009-11-27       Impact factor: 7.580

Review 7.  Hypertension in rheumatoid arthritis.

Authors:  V F Panoulas; G S Metsios; A V Pace; H John; G J Treharne; M J Banks; G D Kitas
Journal:  Rheumatology (Oxford)       Date:  2008-05-08       Impact factor: 7.580

8.  The role of traditional cardiovascular risk factors among patients with rheumatoid arthritis.

Authors:  Sharmayne R E Brady; Barbora de Courten; Christopher M Reid; Flavia M Cicuttini; Maximilian P J de Courten; Danny Liew
Journal:  J Rheumatol       Date:  2009-01       Impact factor: 4.666

9.  Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?

Authors:  Joachim Listing; Anja Strangfeld; Jörn Kekow; Matthias Schneider; Andreas Kapelle; Siegfried Wassenberg; Angela Zink
Journal:  Arthritis Rheum       Date:  2008-03

10.  The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis.

Authors:  Frederick Wolfe; Kaleb Michaud
Journal:  Arthritis Rheum       Date:  2008-09
View more
  5 in total

1.  [Treatment of cardiovascular risk factors].

Authors:  K Krüger
Journal:  Z Rheumatol       Date:  2016-03       Impact factor: 1.372

2.  [Collation of comorbidities: core competence of internist rheumatologists].

Authors:  K Krüger
Journal:  Z Rheumatol       Date:  2014-08       Impact factor: 1.372

3.  [Prevalence, comorbidity and interdisciplinary treatment of rheumatoid arthritis - Insurance data on outpatient and inpatient care in Baden-Württemberg].

Authors:  A Strahl; O Schneider; J Frankenhauser-Mannuß; S Knapstein; C Hermann; B Lembeck; H-M Lorenz; W Rüther; J Flechtenmacher
Journal:  Z Rheumatol       Date:  2018-03       Impact factor: 1.372

Review 4.  [Strategies for improved healthcare of people with the endemic disease rheumatism exemplified by rheumatoid arthritis].

Authors:  J R Kalden; H Burkhardt; B Buss; U Donhauser-Gruber; U Erstling; E Gromnica-Ihle; K Karberg; T Karger; C H Kneitz; A Krause; K Krüger; H-M Lorenz; U Müller-Ladner; A Rubbert-Roth; P Steffens-Korbanka; H-P Tony; J Wendler; J Wollenhaupt; G Burmester
Journal:  Z Rheumatol       Date:  2011-10       Impact factor: 1.372

5.  [Risk of atherosclerosis mediated by inflammation in rheumatoid arthritis].

Authors:  S Kleinert; K Krueger; S Störk
Journal:  Z Rheumatol       Date:  2012-12       Impact factor: 1.372

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.